Hisamitsu Pharmaceutical

The three-way merger that made Hisamitsu a joint-stock company (1951)

Key decision·1951· Hisamitsu Pharmaceutical — the full company history →

Becoming a corporation, forging shop and all

What the February 1951 merger replaced was not the medicine sold but the registration of the company selling it. Of the three entities bundled together, Tashiro Koki Kogyo handled mining machinery and forgings and had nothing to do with either Asahi Mankinko or Salonpas. Miyaki Pharmaceutical, too, had been set up in May 1944 only to hive off drug manufacturing under wartime controls. Three mismatched companies were wound together in order to convert an unlimited partnership — the form the business had held since December 1903 — into a joint-stock company. Hisamitsu Brothers Co., Ltd., with Nakatomi Masayoshi as president, acquired that day the right to issue shares and raise money from outside.

The right to issue shares, however, was the same thing as the duty to keep explaining results and intentions to outsiders. Eleven years passed between acquiring the right and using it; from the September 1962 listing on the second section of the Tokyo Stock Exchange and the Fukuoka exchange, Hisamitsu has stood on the explaining side every period since. The name changed from the Komatsuya opened at Tashiro in 1847, but the head office never left Tashiro in Tosu, and the Nakatomi family kept running it. And in 2026 the company decided to go private, citing investment abroad. Both the right to issue shares and the duty to keep explaining were given up together, seventy-five years on.

Read the full dossier in Japanese →

The Japanese edition carries the complete record of this decision — the situation that forced it, the options weighed, what actually followed, and the sources behind every claim.

Other key decisions at Hisamitsu Pharmaceutical


Yen amounts are converted at the average rate of each figure’s own year — not today’s rate; the revenue chart is shown in yen. Exchange rates & sources — the full ¥/US$ table →


Disclaimer

  • This page is provided for general information only and is not investment advice, nor a recommendation to buy or sell any security.
  • Figures are compiled independently and include our own estimates, approximations and machine-processed data; we make no warranty as to their accuracy or completeness.
  • Sources are primarily each company’s securities reports and other public filings, but errors and omissions may remain.
  • Any use of this information is at the reader’s own risk. Past performance does not indicate future results.
  • Company names, logos and other marks belong to their respective owners.

Data API

Hisamitsu Pharmaceutical’s history, financials, executives and shareholders are published as static JSON — no key, plain GET. Full specification →

Method Endpoint Returns
GET /api/companies.json All companies
GET /api/4530/manifest.json Resource index
GET /api/4530/history.json History overview
GET /api/4530/timeline.json Chronology
GET /api/decisions.json All management decisions (index)
GET /api/4530/decisions.json Management decisions (index)
GET /api/4530/decisions/{slug}.json One decision (full dossier)
GET /api/4530/executives.json Executives
GET /api/4530/shareholders.json Major shareholders
GET /api/4530/financials.json Financial statements
GET /api/4530/financials-longterm.json Long-term results
GET /api/4530/segments.json Business segments
GET /api/4530/regions.json Sales by region
GET /api/4530/workforce.json Workforce